amended. The
forward-looking statements are based on Human Genome Sciences' current
intent, belief and expectations. These statements are not guarantees of
future performance and are subject to certain risks and uncertainties that
are difficult to predict. Actual results may differ materially from these
forward-looking statements because of the Company's unproven business
model, its dependence on new technologies, the uncertainty and timing of
clinical trials, the Company's ability to develop and commercialize
products, its dependence on collaborators for services and revenue, its
substantial indebtedness and lease obligations, its changing requirements
and costs associated with planned facilities and clinical trials, intense
competition, the uncertainty of patent and intellectual property
protection, the Company's dependence on key management and key suppliers,
the uncertainty of regulation of products, the impact of future alliances
or transactions and other risks described in the Company's filings with the
Securities and Exchange Commission. In addition, the Company will continue
to face risks related to animal and human testing, to the manufacture of
ABthrax and to FDA concurrence that ABthrax meets the requirements of the
ABthrax contract. If the Company is unable to meet the product requirements
associated with the ABthrax contract, the U.S. Government will not be
required to reimburse the Company for the costs incurred or to purchase any
ABthrax doses. Existing and prospective investors are cautioned not to
place undue reliance on these forward-looking statements, which speak only
as of today's date. Human Genome Sciences undertakes no obligation to
update or revise the information contained in this announcement whether as
a result of new information, future events or circumstances or otherwise.
'/>"/>SOURCE Human Genome Sciences, Inc. Copyright©2008 PR Newswire. All rights reserved | |
Page: 1 2 Related biology technology :1.
Human Pheromone Sciences, Inc. - Shareholder Update2.
The human brain minimizes energy expenditure and integrates gravity in to the action plan3.
EntreMeds ENMD-2076 Demonstrates Tumor Regression in Human Colon Cancer Model4.
Humanitarian Offers $75 Million for Single Dose Sterilization of Cats and Dogs5.
Pioneer(R) Surgical Technology Announces First Human Implants of New nanOss(TM)-Cervical Fusion Device6.
Complete Genomics Launches, Becomes Worlds First Large-Scale Human Genome Sequencing Company7.
Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at JMP Securities Conference8.
Isis Announces Award of Up to $8.4 Million in New Government Grants and Contracts to Its Ibis Biosciences Subsidiary for Pathogen Detection and Human Forensics9.
Pigs bred with cystic fibrosis provide model to mimic human disease10.
Histogen Launches BioNuesis, the Only All-Human Stem Cell Culturing Kit11.
Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at UBS Conference